Missing: Kinetek Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Kinetek Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Kinetek Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Kinetek Pharmaceuticals's headquarters?
Kinetek Pharmaceuticals's headquarters is located at Vancouver.
What is Kinetek Pharmaceuticals's latest funding round?
Kinetek Pharmaceuticals's latest funding round is Acquired.
Who are the investors of Kinetek Pharmaceuticals?
Investors of Kinetek Pharmaceuticals include QLT.
Who are Kinetek Pharmaceuticals's competitors?
Competitors of Kinetek Pharmaceuticals include Bloomage BioTech, Achillion Pharmaceuticals, Array Biopharma, Viventia, Cubist Pharmaceuticals and 12 more.
Compare Kinetek Pharmaceuticals to Competitors
NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.
Quincy Bioscience is a biotechnology company focused on the discovery, development and commercialization of novel technologies to support cognitive function and other age-related health challenges such as memory. The company's products focus on supporting memory and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the patented protein apoaequorin, which is breaking new ground in supporting brain cells in normal aging.
Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).
Exigent Pharmaceuticals is a new biopharmaceutical company focused on the development and commercialization of anti-infectives. Exigent is currently developing new pharmaceuticals to treat drug-resistant bacterial infections, using its technology platform.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.